Novartis: presents benefits of Kisqali
(CercleFinance.com) - Novartis has presented the unprecedented overall survival benefits of Kisqali in patients with advanced breast cancer and difficult visceral metastases.
The combination of Kisqali and endocrine therapy results in a median survival of approximately five years in patients with visceral metastases, adding a survival advantage of nearly one year in this more difficult-to-treat population.
Kisqali is a unique CDK4/6 inhibitor that has consistently demonstrated a statistically significant overall survival benefit, while maintaining or improving the quality of life in three Phase III trials, independent of patient or disease characteristics.
Data from this analysis will be presented at the European Society for Medical Oncology (ESMO) Congress in Paris, France.
Copyright (c) 2022 CercleFinance.com. All rights reserved.
The combination of Kisqali and endocrine therapy results in a median survival of approximately five years in patients with visceral metastases, adding a survival advantage of nearly one year in this more difficult-to-treat population.
Kisqali is a unique CDK4/6 inhibitor that has consistently demonstrated a statistically significant overall survival benefit, while maintaining or improving the quality of life in three Phase III trials, independent of patient or disease characteristics.
Data from this analysis will be presented at the European Society for Medical Oncology (ESMO) Congress in Paris, France.
Copyright (c) 2022 CercleFinance.com. All rights reserved.